Portola Pharmaceuticals, Inc.
PTLA
PTLA was delisted on the 1st of July, 2020.
197 hedge funds and large institutions have $1.88B invested in Portola Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 76 increasing their positions, 62 reducing their positions, and 30 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 62
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
2% more call options, than puts
Call options by funds: $23.6M | Put options by funds: $23.2M
3% less funds holding
Funds holding: 204 → 197 (-7)
20% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 30
20% less capital invested
Capital invested by funds: $2.36B → $1.88B (-$476M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadian Capital Management
New York
|
+$61.2M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
+$59.5M |
| 3 |
JSP
Jackson Square Partners
Larkspur,
California
|
+$33M |
| 4 |
DM
Deerfield Management
New York
|
+$32.9M |
| 5 |
State Street
Boston,
Massachusetts
|
+$24.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$15.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.3M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$12M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$10.4M |
| 5 |
D.E. Shaw & Co
New York
|
-$9.51M |
PTLA Hedge Fund Activity: Q3 2018 in Review
197 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q3 2018, worth a combined $1.88B — down 20% from $2.36B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of PTLA and 24 opened new positions — a net loss of 6 holders — while 62 trimmed existing stakes and 76 added.
The largest buyer was Cadian Capital Management, adding an estimated $61.2M. The largest seller was PFM Health Sciences, cutting an estimated $15.6M.
- 197 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q3 2018, down from 204 in Q2 2018.
- Funds reported $1.88B of Portola Pharmaceuticals, Inc. stock for Q3 2018, down 20% quarter-over-quarter.
- 24 funds opened new Portola Pharmaceuticals, Inc. positions in Q3 2018 and 30 closed out, a net change of -6 holders.
- The largest Portola Pharmaceuticals, Inc. buyer in Q3 2018 was Cadian Capital Management, an estimated $61.2M added.
- The largest Portola Pharmaceuticals, Inc. seller in Q3 2018 was PFM Health Sciences, an estimated $15.6M sold.
Based on aggregated 13F filings for Q3 2018.